TB-500(胸腺素β4 17-23片段)用于稳定ASCVD心血管生物标志物 (TBRIDGE-CV)
一项针对稳定型动脉粥样硬化性心血管疾病成人患者的TB-500(胸腺素β4 17-23片段)1/2期、随机、双盲、安慰剂对照、序贯剂量递增研究,旨在评估其安全性、耐受性、药代动力学及探索性心血管生物标志物
Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers
研究概览
详细说明
Design overview: Participants with stable ASCVD will be enrolled into three sequential dose cohorts. Within each cohort, participants are randomized in a 3:1 ratio to TB-500 or matching placebo. Masking is maintained for participants, care providers, investigators, and outcome assessors. Intervention period: Study drug is administered by trained clinic staff during scheduled on-site visits over an 8-week dosing period, followed by a 4-week safety follow-up. The specific dose levels are protocol-defined and are not provided in this public example. Assessments: Safety assessments include adverse events, concomitant medications, physical examinations, vital signs, clinical laboratory testing, and 12-lead ECG. Exploratory cardiovascular assessments include brachial artery flow-mediated dilation (FMD) and blood-based biomarkers of inflammation and cardiac stress. Escalation and oversight: An independent safety review committee evaluates cumulative safety data after each cohort completes early follow-up before enrollment begins in the next cohort.
研究类型
注册 (估计的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习联系方式
- 姓名:Seni Lu, Phd
- 电话号码:+86 13076790030
- 邮箱:Seni-Lu@beijing-biotech.com
学习地点
-
-
Guangdong
-
Shenzhen、Guangdong、中国、518036
- 招聘中
- Peking University Shenzhen Hospital
-
接触:
- Zhen J Peng, Phd
- 电话号码:+86 13076790039
- 邮箱:Zhen-Peng@beijing-biotech.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 40-75 years, able to provide written informed consent.
- Documented stable ASCVD (e.g., prior myocardial infarction >6 months ago, prior coronary revascularization, stable angina with objective evidence of ischemia, or symptomatic peripheral artery disease).
- On stable guideline-directed medical therapy (e.g., statin and antiplatelet therapy unless contraindicated) for at least 8 weeks before screening.
- Resting systolic blood pressure <160 mmHg and diastolic blood pressure <100 mmHg (with or without therapy).
- Able and willing to comply with study visits and procedures.
Exclusion Criteria:
- Acute coronary syndrome, stroke/transient ischemic attack, or coronary revascularization within 6 months before screening.
- New York Heart Association (NYHA) class III-IV heart failure or left ventricular ejection fraction <35%.
- Clinically significant arrhythmia requiring recent hospitalization or unstable antiarrhythmic therapy.
- Severe renal impairment (eGFR <30 mL/min/1.73 m^2) or end-stage renal disease.
- Clinically significant hepatic impairment (e.g., Child-Pugh class B/C) or ALT/AST >3x upper limit of normal at screening.
- Active malignancy requiring systemic therapy (except adequately treated non-melanoma skin cancer) within the past 2 years.
- Known autoimmune disease requiring systemic immunosuppression, or use of chronic systemic corticosteroids above physiologic replacement.
- Pregnant or breastfeeding, or unwilling to use effective contraception during the study (if of childbearing potential).
- Known hypersensitivity to peptide therapeutics or study formulation components.
- Participation in another interventional clinical study or receipt of an investigational product within 30 days (or 5 half-lives, whichever is longer) prior to screening.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:匹配安慰剂
|
(thymosin beta 4 17-23 fragment matching vehicle |
|
实验性的:TB-500 低剂量
|
(thymosin beta 4 17-23 fragment matching vehicle |
|
实验性的:TB-500 中等剂量
|
(thymosin beta 4 17-23 fragment matching vehicle |
|
实验性的:TB-500 高剂量
|
(thymosin beta 4 17-23 fragment matching vehicle |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
严重不良事件(SAE)发生率
大体时间:28天
|
28天
|
|
|
incidence of treatment-emergent adverse events (TEAEs)
大体时间:12 weeks
|
Proportion of participants with at least one TEAE/SAE; severity and relationship assessed by investigator. |
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Brachial artery flow-mediated dilation (FMD)
大体时间:8 weeks
|
Change from baseline in percent FMD measured by standardized ultrasound protocol |
8 weeks
|
|
High-sensitivity C-reactive protein (hs-CRP)
大体时间:8 weeks
|
Change from baseline in hs-CRP concentration. |
8 weeks
|
|
NT-proBNP
大体时间:8 weeks
|
Change from baseline in NT-proBNP concentration. |
8 weeks
|
|
Exploratory vascular stiffness
大体时间:8 weeks
|
Change from baseline in carotid-femoral pulse wave velocity (if available at site). |
8 weeks
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.